Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 11—November 2024
Research Letter

Environmental Vibrio cholerae Strains Harboring Cholera Toxin and Vibrio Pathogenicity Island 1, Nigeria, 2008–2015

Sergio MorgadoComments to Author , Akinsinde Adewale, Iwalokun Abiodun, Salako Lawal, Fernanda Freitas, Érica Fonseca, and Ana Carolina Vicente
Author affiliation: Instituto Oswaldo Cruz, Rio de Janeiro, Brazil (S. Morgado, F. Freitas, É. Fonseca, A.C. Vicente); Nigerian Institute of Medical Research, Yaba, Nigeria (A. Adewale, I. Abiodun, S. Lawai)

Main Article

Table

Antimicrobial susceptibility profile of environmental and clinical strains of Vibrio cholerae, Nigeria*

Strains Lineage Source Isolation date ICE STX GEN STR NAL CIP SUL SXT TET CHL
VC18 VC19 VC21 VC25 VC66 Afr9 Clinical 2008/2010 + S R S S R R S S
VC23 VC62 Afr9 Clinical 2007/2010 – S I S S S S S S
VC64 Afr9 Water 2007 – S I S S S S S S
VC29 VC30 VC31 VC40 VC47
VC73 VC74 VC84 VC100		 Afr12 Clinical 2008/2009/2010/2013/2015 + S R R S R R S I
VC105 Afr12 Water 2009 – S I R S S S S S
VC49 VC52 VC108 Afr12 Water 2009/2010 + S R R S R R S I
VC89 VC96 VC97 Afr12 Unknown Unknown + S R R S R R S I

*Phenotypic resistance was determined according to Clinical and Laboratory Standards Institute breakpoints (6,7). CHL, chloramphenicol; CIP, ciprofloxacin; GEN, gentamicin; ICE, integrative and conjugative element; NAL, nalidixic acid; STR, streptomycin; SUL, sulfonamide; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; +, indicates presence of the region with antimicrobial resistance genes in ICE STX; –, indicates absence of the region with antimicrobial resistance genes in ICE STX.

Main Article

References
  1. Charnley  GEC, Jean  K, Kelman  I, Gaythorpe  KAM, Murray  KA. Association between conflict and cholera in Nigeria and the Democratic Republic of the Congo. Emerg Infect Dis. 2022;28:2472–81. DOIPubMedGoogle Scholar
  2. World Health Organization. Cholera in the WHO African Region: Weekly Regional Cholera Bulletin: 18 December 2023 [cited 2024 Mar 25]. https://iris.who.int/bitstream/handle/10665/375789/AFRO%20Cholera%20Bulletin.43.pdf
  3. Weill  FX, Domman  D, Njamkepo  E, Tarr  C, Rauzier  J, Fawal  N, et al. Genomic history of the seventh pandemic of cholera in Africa. Science. 2017;358:785–9. DOIPubMedGoogle Scholar
  4. Ramamurthy  T, Mutreja  A, Weill  FX, Das  B, Ghosh  A, Nair  GB. Revisiting the global epidemiology of cholera in conjunction with the genomics of Vibrio cholerae. Front Public Health. 2019;7:237. DOIPubMedGoogle Scholar
  5. Marin  MA, Thompson  CC, Freitas  FS, Fonseca  EL, Aboderin  AO, Zailani  SB, et al. Cholera outbreaks in Nigeria are associated with multidrug resistant atypical El Tor and non-O1/non-O139 Vibrio cholerae. PLoS Negl Trop Dis. 2013;7:e2049. DOIPubMedGoogle Scholar
  6. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline. 3rd ed. Austin (TX); The Institute; 2010.
  7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 26th ed. Supplement M100S. Wayne (PA): The Institute; 2016.
  8. Hounmanou  YMG, Njamkepo  E, Rauzier  J, Gallandat  K, Jeandron  A, Kamwiziku  G, et al. Genomic Microevolution of Vibrio cholerae O1, Lake Tanganyika Basin, Africa. Emerg Infect Dis. 2023;29:149–53. DOIPubMedGoogle Scholar
  9. World Health Organization. Ending cholera: a global roadmap to 2030 [cited 2024 Mar 25]. https://www.gtfcc.org/wp-content/uploads/2019/10/gtfcc-ending-cholera-a-global-roadmap-to-2030.pdf
  10. Kaseya  J, Dereje  N, Tajudeen  R, Ngongo  AN, Ndembi  N, Fallah  MP. Climate change and malaria, dengue and cholera outbreaks in Africa: a call for concerted actions. BMJ Glob Health. 2024;9:e015370. DOIPubMedGoogle Scholar

Main Article

Page created: September 30, 2024
Page updated: October 23, 2024
Page reviewed: October 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external